• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, February 7, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

Immunotherapy trial cures Tasmanian devils of DFTD

Bioengineer by Bioengineer
March 9, 2017
in Science News
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
IMAGE

Credit: shutterstock

An international study involving multiple institutions over six years has shown that immunotherapy can cure Tasmanian devils of the deadly devil facial tumour disease (DFTD).

The research was led by the University of Tasmania's Menzies Institute for Medical Research with input from the School of Medicine. It also involved the Walter and Eliza Hall Institute of Medical Research, CSL Ltd, and the Universities of Sydney, Southampton, Southern Denmark and Cambridge.

Professor Greg Woods, the leader of the DFTD team at Menzies, said scientists used immunotherapy on devils with a golf-ball sized tumours and then observed the tumours gradually shrinking and disappearing over three months. "This is almost a Eureka moment for us because it's the first time we can say for sure that it was the immunotherapy that was making the tumour shrink," Professor Woods said.

Building a good understanding of the devil's immune system, which goes hand in hand with the development of a vaccine, involves years of painstaking laboratory work. The process is incremental, but with each step scientists are closing in on the disease. This breakthrough is the next step on from work published in 2015 that showed that the devil's immune system was capable of mounting an immune response to DFTD.

Professor Woods said the latest work underlined that the devil's immune system is its best ally against DFTD. "This is an important step along the way to developing a vaccine to protect against DFTD and potentially for immunotherapy to cure devils of established DFTD," he said.

Dr Cesar Tovar is the lead author on the latest paper. He said the results were very encouraging as they confirmed that it was possible to trigger the devil's immune system to recognise and destroy established DFTD tumours. "Our research shows that a DFTD vaccine is feasible. We are focusing our efforts on developing strategies to improve the devils' response to immunisation," Dr Tovar said.

The research was published in Scientific Reports. It was funded by the Australian Research Council, the National Health and Medical Research Council and the WellcomeTrust, with additional support from the University of Tasmania Foundation through funds raised by the Save the Tasmanian Devil Appeal.

###

Professor Woods said the support of the Save the Tasmanian Devil Appeal was critical for ongoing work.

C Tovar, RJ Pye, A Kreiss, Y Cheng, GK Brown, JM Darby, RC. Malley, HV Siddle, K Skjodt, J Kaufman, A Silva, A Baz Morelli, AT Papenfuss, LM Corcoran, JM Murphy, MJ Pearse, K Belov, AB Lyons and GM. Woods (2017). "Regression of devil facial tumour disease following immunotherapy in immunised Tasmanian devils." Scientific Reports

The paper is available here once published: http://www.nature.com/articles/srep43827

Media Contact

Miranda Harman
[email protected]
61-042-719-9562

http://www.utas.edu.au/

############

Story Source: Materials provided by Scienmag

Share12Tweet8Share2ShareShareShare2

Related Posts

Evaluating Pediatric Emergency Care Quality in Ethiopia

February 7, 2026

TPMT Expression Predictions Linked to Azathioprine Side Effects

February 7, 2026

Improving Dementia Care with Enhanced Activity Kits

February 7, 2026

Decoding Prostate Cancer Origins via snFLARE-seq, mxFRIZNGRND

February 7, 2026
Please login to join discussion

POPULAR NEWS

  • Robotic Ureteral Reconstruction: A Novel Approach

    Robotic Ureteral Reconstruction: A Novel Approach

    82 shares
    Share 33 Tweet 21
  • Digital Privacy: Health Data Control in Incarceration

    63 shares
    Share 25 Tweet 16
  • Study Reveals Lipid Accumulation in ME/CFS Cells

    57 shares
    Share 23 Tweet 14
  • Breakthrough in RNA Research Accelerates Medical Innovations Timeline

    53 shares
    Share 21 Tweet 13

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Evaluating Pediatric Emergency Care Quality in Ethiopia

TPMT Expression Predictions Linked to Azathioprine Side Effects

Improving Dementia Care with Enhanced Activity Kits

Subscribe to Blog via Email

Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm' to start subscribing.

Join 73 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.